Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma: Case Report.

Abstract

The spread of next-generation sequencing enables clinicians to identify rare oncogene alterations, including MET exon 14 skipping mutation, in clinical practice for NSCLC. Several tyrosine kinase inhibitors for MET exon 14 skipping mutation such as capmatinib and tepotinib have elucidated their effectiveness. Only a few reports have suggested their efficacy against central nervous system lesions, especially leptomeningeal metastases. We here report a case of a patient with NSCLC with MET exon 14 skipping mutation and poor performance status salvaged by marked leptomeningeal metastases response to tepotinib. We further provide measures of plasma/cerebrospinal fluid concentrations of tepotinib and its cerebrospinal fluid penetration rate.

• Authors: Taira Ninomaru, Hideaki Okada, Mika Fujishima, Kei Irie, Shoji Fukushima, Akito Hata
• Journal: JTO clinical and research reports (JTO Clin Res Rep) Vol. 2 Issue 3 Pg. 100145 (Mar 2021) ISSN: 2666-3643 [Electronic] United States
• PMID: 34590003 (Publication Type: Case Reports)
• Copyright: © 2021 The Authors.